WASHINGTON — The Antiviral Drugs Advisory Committee of the Food and Drug Administration recommended the agency approve for preventative use Gilead’s AIDS treatment drug Truvada, according to MSNBC.
Testing has shown promise with high-risk patients in preventing HIV infection when taking the drug daily. Though concerns have been raised over the drug’s cost ($1,200 per month), the possibility for creating drug-resistant strains of the virus and side effects like nausea, HIV prevention specialists welcome the decision as part of a comprehensive toolkit to reducing new infections.
“Existing interventions have not reduced the number of new infections annually and new measures are needed,” Dr. John Mellors, chief of the infectious diseases division at the University of Pittsburgh, told MSNBC.
- Biden to sign EO implementing Supreme Court ruling for LGBTQ rights by Chris Johnson | posted on January 20, 2021
- Maryland name change bill reintroduced by Philip Van Slooten | posted on January 18, 2021
- Prominent D.C. Realtor, avid traveler Kurt Rieschick dies at 50 by Lou Chibbaro Jr. | posted on January 20, 2021
- Rachel Levine tapped to become first out transgender Senate-confirmed official by Chris Johnson | posted on January 19, 2021
- Md., Va. lawmakers introduce bills to ban LGBTQ panic defense by Philip Van Slooten | posted on January 19, 2021